# US 2021/0277060 A1 · 14-3-3 targeting peptides for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277060 A1
- Document ID: US20210277060A1
- Status: Published application
- Kind: A1
- Application number: 17/314,795
- Filed: 2021-05-07
- Published: 2021-09-09
- Earliest claimed: 2019-05-08
- Assignees: Creighton University
- Applicants: Creighton University; The Board of Regents of the University of Nebraska
- Inventors: Laura Hansen; Sandor Lovas; Nicholas Palermo
- Web page: https://patentgrep.com/patent/US20210277060A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 35/00: Antineoplastic agents
- C07K 5/1024: {with the first amino acid being heterocyclic}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO32−)-Ala-Pro-Ala-Arg-NH2 (SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32−)-Trp-Ala-Gly-NH2 (SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.

## Claims

### Claim 1

A peptide, the peptide having the formula: X-R1-R2-R3-R4-Ser-(PO32−)-R5-Pro-R6-Arg-Y, wherein
X represents hydrogen, acetyl or propionyl group,
R1 represents an L or D-amino acid residue selected from the group consisting of: Gln, Trp, Tyr, Phe, His,
R2 represents an L or D-amino acid residue selected from the group consisting of: Arg, Lys, Orn,
R3 represents an L or D-amino acid residue selected from the group consisting of: Gln, Arg, Lys, Orn, Pro, Trp, Tyr, Phe, His,
R4 represents an L or D-amino acid residue selected from the group consisting of: Asn, Arg, Lys, Orn, Trp, Tyr, Phe, His,
R5 represents an L or D-amino acid residue selected from the group consisting of: Ala, Trp, Tyr, Phe, His,
R6 represents an L or D-amino acid residue selected from the group consisting of: Ala, Trp, Tyr, Phe, His, and
Y represents —OH, amide, methylamide, or ethylamide groups.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide promotes apoptosis in squamous cell carcinoma cells.

### Claim 3 (depends on 1)

The peptide of claim 1, further comprising a pharmaceutically acceptable carrier selected from the group consisting of an emulsion, a lotion, a cream, a gel, a water-immiscible solvent, an emollient, and combinations thereof.

### Claim 4 (depends on 1)

The peptide of claim 1, further comprising a pharmaceutically acceptable carrier suitable for administration via at least one of administration via injection, topical administration, aerosol administration, administration via inhalation, oral administration, systemic IV application, ocular administration, and rectal administration.

### Claim 5 (depends on 1)

A method of reducing squamous cell carcinoma survival comprising contacting a squamous cell carcinoma cell with a peptide of claim 1.

### Claim 6

A peptide, the peptide having the formula: X-R1-Thr-R2-R3-R4-Thr(PO32−)-R5-R6-R7-Y, wherein
X represents hydrogen, acetyl or propionyl group,
R1 represents an L or D-amino acid residue selected from the group consisting of: Arg, Trp, Tyr, Phe, His,
R2 represents an L or D-amino acid residue selected from the group consisting of: Lys, Arg, Orn,
R3 represents an L or D-amino acid residue selected from the group consisting of: Ser, Arg, Lys, Orn, Pro, Trp, Tyr, Phe, His,
R4 represents an L or D-amino acid residue selected from the group consisting of: Arg, Lys, Orn, Trp, Tyr, Phe, His,
R5 represents an L or D-amino acid residue selected from the group consisting of: Trp, Ala, Tyr, Phe, His,
R6 represents an L or D-amino acid residue selected from the group consisting of: Ala, Pro, R7 represents L-Glycine or an L or D-amino acid residue selected from the group consisting of: Trp, Tyr, Phe, His, and
Y represents —OH, amide, methylamide, or ethylamide groups.

### Claim 7 (depends on 6)

The peptide of claim 6, wherein the peptide promotes apoptosis in squamous cell carcinoma cells.

### Claim 8 (depends on 6)

The peptide of claim 6, further comprising a pharmaceutically acceptable carrier selected from the group consisting of an emulsion, a lotion, a cream, a gel, a water-immiscible solvent, an emollient, and combinations thereof.

### Claim 9 (depends on 6)

The peptide of claim 6, further comprising a pharmaceutically acceptable carrier suitable for administration via at least one of administration via injection, topical administration, aerosol administration, administration via inhalation, oral administration, systemic IV application, ocular administration, and rectal administration.

### Claim 10 (depends on 6)

A method of reducing squamous cell carcinoma survival comprising contacting a squamous cell carcinoma cell with a peptide of claim 6.

### Claim 11

A peptide, the peptide having the formula: X-arg-R1-pro-R2-ser-(PO32−)-R3-R4-R5-R6-Y, wherein
X represents hydrogen, acetyl or propionyl group,
arg represents D-Arginine,
R1 represents a D-amino acid residue selected from the group consisting of: Ala, Trp, Tyr, Phe, His,
pro represents D-Proline,
R2 represents a D-amino acid residue selected from the group consisting of: Ala, Trp, Tyr, Phe, His,
ser represents D-Serine,
R3 represents a D-amino acid residue selected from the group consisting of: Asn, Arg, Lys, Orn, Trp, Tyr, Phe, His,
R4 represents a D-amino acid residue selected from the group consisting of: Gln, Arg, Lys, Orn, Pro, Trp, Tyr, Phe, His,
R5 represents a D-amino acid residue selected from the group consisting of: Arg, Lys, Orn,
R6 represents a D-amino acid residue selected from the group consisting of: Gln, Trp, Tyr, Phe, His, and
Y represents —OH, amide, methylamide, or ethylamide groups.

### Claim 12

A peptide, the peptide having the formula: X-R1-R2-R3-thr(PO32−)-R4-R5-R6-thr-R7-Y, wherein
X represents hydrogen, acetyl or propionyl group,
R1 represents L-Glycine or a D-amino acid residue selected from the group consisting of: Trp, Tyr, Phe, His,
R2 represents an L or D-amino acid residue selected from the group consisting of: Ala, Pro,
R3 represents an L or D-amino acid residue selected from the group consisting of: Trp, Ala, Tyr, Phe, His,
thr represents D-Threonine,
R4 represents an L or D-amino acid residue selected from the group consisting of: Arg, Lys, Orn, Trp, Tyr, Phe, His,
R5 represents an L or D-amino acid residue selected from the group consisting of: Ser, Arg, Lys, Orn, Pro, Trp, Tyr, Phe, His,
R6 represents an L or D-amino acid residue selected from the group consisting of: Lys, Arg, Orn,
R7 represents an L or D-amino acid residue selected from the group consisting of: Arg, Trp, Tyr, Phe, His, and
Y represents —OH, amide, methylamide, or ethylamide groups.
